STRO

Sutro Biopharma, Inc. [STRO] Stock Forecast

Q: What is Sutro Biopharma, Inc. stock symbol ?

Sutro Biopharma, Inc. is a US stock, located in South san francisco of Ca and trading under the symbol STRO

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

STRO Stock Summary

Earnings have grown 9.52% per last year.

The Moving Average Convergence Divergence (MACD) for STRO recently turned positive (within last 10 days).

Earnings are expected to fall -10.32% next year

EPS has been decreasing for the past 3 years (Yearly statements)

EPS has been decreasing for the past 3 quarters (Quarter statements)

Currently unprofitable, and not expected to turn profitable in the coming year

Profit margins (-1.78%) are lower than the previous year (-1.76%)

STRO has less than 1 year of cash runway

Top 10 Correlated ETFs

STRO

Top 10 Correlated Stocks

STRO

In the News

10:41 10 Jun 2023 STRO

Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates

Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.84 per share a year ago.

08:00 10 Jun 2023 STRO

Sutro Biopharma to Present at the JMP Securities Life Sciences Conference

SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Monday, May 15th, 2023, at 2:00 p.m. ET / 11:00 a.m. PT in New York City.

05:21 10 Jun 2023 STRO

Sutro Biopharma, Inc. (STRO) Soars 11.3%: Is Further Upside Left in the Stock?

Sutro Biopharma, Inc. (STRO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

01:17 10 Jun 2023 STRO

Sutro: Too Little, Too Late For STRO-002, But Platform Is Interesting

STRO is playing second fiddle to perpetually second fiddle player ImmunoGen in ovarian cancer. Although there are certain positive aspects to the molecule, I see little traction here.

08:01 10 Jun 2023 STRO

Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Misses Revenue Estimates

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 4.69% and 24.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

08:00 10 Jun 2023 STRO

Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in an Ovarian Cancer panel discussion at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023, at 9:10 a.m. ET / 6:10 a.m. PT in Boston, MA.

08:00 10 Jun 2023 STRO

Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA.

07:00 10 Jun 2023 STRO

Sutro Biopharma to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences.

07:00 10 Jun 2023 STRO

Sutro Biopharma to Present at the 2022 Wells Fargo Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 2022 Wells Fargo Healthcare Conference on Friday, September 9, 2022, at 10:25 a.m. ET / 7:25 a.m. PT in Boston.

01:05 10 Jun 2023 STRO

Sutro Biopharma: Partnership Progress Warrants Exposure

Shares of Sutro Biopharma have lost one-third of their value over the past 3 years. Consolidation in the antibody drug conjugate space has made it an attractive area for drug development.

STRO Financial details

Company Rating

Neutral

Market Cap

322.02M

Income

-130.92M

Revenue

74.55M

Book val./share

3.16

Cash/share

4.71

Dividend

Dividend %

Employees

292

Optionable

Shortable

Yes

Earnings

07 Aug 2023

P/E

-2.36

Forward P/E

PEG

-2.1

P/S

4.32

P/B

1.69

P/C

1.13

P/FCF

-10.94

Quick Ratio

2.27

Current Ratio

2.27

Debt / Equity

0.35

LT Debt / Equity

0.25

EPS (TTM)

-2.47

EPS next Y

EPS next Q

-0.56

EPS this Y

5.86%

EPS next Y

EPS next 5Y

20.24%

EPS last 5Y

-17.45%

Revenue last 5Y

12.02%

Revenue Q/Q

46.83%

EPS Q/Q

16.44%

SMA20

-16.67%

SMA50

SMA100

-37.5%

Inst Own

100%

Inst Trans

4.55%

ROA

-37%

ROE

-63%

ROC

-0.57%

Gross Margin

100%

Oper. Margin

-177%

Profit Margin

-178%

Payout

Shs Outstand

60.42M

Shs Float

46.25M

Target Price

21.5

52W Range

3.33-8.72

52W High

-33.69%

52W Low

+76.83%

RSI

Rel Volume

0.51

Avg Volume

483.02K

Volume

247.49K

Perf Week

6.31%

Perf Month

3.61%

Perf Quarter

-24.21%

Perf Half Y

-28.21%

Beta

0.884552

Volatility

0.05%, 0.35%

Prev Close

3.61%

Price

5.305

Change

3.82%

STRO Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	6.67	1.86	1.31	1.34	1.34
Net income per share	-6.13	-2.44	-0.99	-2.22	-2.35
Operating cash flow per share	2.2	-2.83	-2.08	-1.77	0.07
Free cash flow per share	1.93	-2.98	-2.3	-2.1	-0.08
Cash per share	35.51	5.13	11.3	4.29	6.59
Book value per share	22.84	4.26	10.19	5.48	4.28
Tangible book value per share	22.84	4.26	10.19	5.48	4.28
Share holders equity per share	22.84	4.26	10.19	5.48	4.28
Interest debt per share	2.84	0.62	0.88	1.31	1.4
Market cap	51.95M	252.54M	707.17M	686.25M	409.97M
Enterprise value	-58.63M	257.46M	525.56M	713.21M	430.23M
P/E ratio	-1.47	-4.51	-22.01	-6.7	-3.44
Price to sales ratio	1.35	5.91	16.55	11.09	6.05
POCF ratio	4.1	-3.88	-10.43	-8.4	115.52
PFCF ratio	4.67	-3.69	-9.44	-7.07	-95.14
P/B Ratio	0.39	2.58	2.13	2.72	1.89
PTB ratio	0.39	2.58	2.13	2.72	1.89
EV to sales	-1.53	6.02	12.3	11.53	6.35
Enterprise value over EBITDA	2.01	-5.52	-8.05	-7.66	-3.43
EV to operating cash flow	-4.62	-3.96	-7.75	-8.73	121.23
EV to free cash flow	-5.27	-3.76	-7.01	-7.35	-99.85
Earnings yield	-0.68	-0.22	-0.05	-0.15	-0.29
Free cash flow yield	0.21	-0.27	-0.11	-0.14	-0.01
Debt to equity	0.11	0.1	0.07	0.23	0.31
Debt to assets	0.07	0.06	0.06	0.17	0.17
Net debt to EBITDA	3.79	-0.11	2.78	-0.29	-0.16
Current ratio	5.76	3.9	12.78	5.24	2.22
Interest coverage	-22.93	-12.75	-17.43	-31.41	-38.54
Income quality	-0.36	1.17	2.11	0.77	-0.03
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.56	0.76	0.86	0.91	0.88
Research and developement to revenue	1.41	1.54	1.8	1.69	2.02
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	-0.12	0.05	0.11	0.19	-2.21
Capex to revenue	-0.04	-0.08	-0.17	-0.25	-0.12
Capex to depreciation	-0.34	-0.73	-1.66	-3.16	-1.38
Stock based compensation to revenue	0.07	0.24	0.28	0.38	0.39
Graham number	56.14	15.29	15.04	16.54	15.04
ROIC	1.22	-0.4	-0.87	-0.36	-0.47
Return on tangible assets	-0.16	-0.36	-0.08	-0.3	-0.29
Graham Net	19.93	2.79	9.52	2.57	2.95
Working capital	173.52M	95.6M	348.59M	176.78M	170M
Tangible asset value	131.54M	97.79M	332.05M	252.56M	217.05M
Net current asset value	118.35M	69.99M	316.12M	129.67M	119.57M
Invested capital	0.11	0.1	0.07	0.23	0.31
Average receivables	2.06M	4.39M	5.93M	9.01M	9.79M
Average payables	2.98M	4.32M	5.56M	8.44M	22.07M
Average inventory	0	0	0	0	0
Days sales outstanding	23.65	53.79	47.49	73.46	38.36
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	15.44	6.79	7.69	4.97	9.52
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.27	-0.57	-0.1	-0.41	-0.55
Capex per share	-0.27	-0.15	-0.22	-0.33	-0.15

Quarterly Fundamentals Overview

Last date of statement is 2023-03-31 for Q1

Metric	2022-03-31	2022-06-30	2022-09-30	2022-12-31	2023-03-31
Revenue per share	0.13	0.6	0.48	0.17	0.22
Net income per share	-0.84	-0.55	-0.37	-0.73	-0.85
Operating cash flow per share	-0.76	-0.07	1.26	-0.47	-1.04
Free cash flow per share	-0.79	-0.11	1.24	-0.54	-1.05
Cash per share	4.5	4.81	6.19	6.59	4.71
Book value per share	4.74	4.45	4.39	4.28	3.16
Tangible book value per share	4.74	4.45	4.39	4.28	3.16
Share holders equity per share	4.74	4.45	4.39	4.28	3.16
Interest debt per share	1.26	1.19	1.06	0.98	1.16
Market cap	382.23M	244.65M	290.52M	409.97M	271.3M
Enterprise value	411.3M	221M	246.69M	413.15M	66.4M
P/E ratio	-2.44	-2.35	-3.73	-2.76	-1.36
Price to sales ratio	64.82	8.71	11.55	47.49	21.41
POCF ratio	-10.84	-76.79	4.41	-17.18	-4.45
PFCF ratio	-10.38	-45.42	4.46	-15.06	-4.38
P/B Ratio	1.73	1.17	1.26	1.89	1.46
PTB ratio	1.73	1.17	1.26	1.89	1.46
EV to sales	69.75	7.87	9.81	47.86	5.24
Enterprise value over EBITDA	-10.91	-12.43	-13.15	-9.07	-1.67
EV to operating cash flow	-11.67	-69.37	3.75	-17.31	-1.09
EV to free cash flow	-11.17	-41.03	3.79	-15.17	-1.07
Earnings yield	-0.1	-0.11	-0.07	-0.09	-0.18
Free cash flow yield	-0.1	-0.02	0.22	-0.07	-0.23
Debt to equity	0.26	0.27	0.23	0.23	0.35
Debt to assets	0.19	0.14	0.13	0.12	0.18
Net debt to EBITDA	-0.77	1.33	2.34	-0.07	5.16
Current ratio	5.9	7.44	5.95	5.31	2.27
Interest coverage	-59.56	-32.62	-7.61	71.03	-14.15
Income quality	0.9	0.12	-3.38	0.69	1.22
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	2.55	0.54	0.58	1.71	1.22
Research and developement to revenue	5.09	1.15	1.26	5	3.11
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.04	0.69	-0.01	0.14	0.02
Capex to revenue	-0.26	-0.08	-0.03	-0.39	-0.07
Capex to depreciation	-1.17	-1.57	-0.51	-2.2	-0.58
Stock based compensation to revenue	1.18	0.24	0.27	0.68	0.48
Graham number	9.47	7.45	6.06	8.39	7.78
ROIC	-0.17	-0.1	-0.1	-0.17	0.25
Return on tangible assets	-0.13	-0.07	-0.05	-0.09	-0.14
Graham Net	2.89	2.61	3.09	2.95	1.9
Working capital	189.98M	286.94M	288.27M	286.61M	160.33M
Tangible asset value	220.37M	209.06M	229.73M	217.05M	185.41M
Net current asset value	145.44M	154.95M	175.58M	163.26M	113.76M
Invested capital	0.26	0.27	0.23	0.23	0.35
Average receivables	12.07M	54.68M	54.46M	9.18M	8.5M
Average payables	11.02M	11.64M	12.51M	8.62M	14.3M
Average inventory	0	0	0	0	0
Days sales outstanding	178.35	312.87	40.23	74.26	70.11
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0.5	0.29	2.24	1.21	1.28
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.18	-0.12	-0.08	-0.17	-0.27
Capex per share	-0.03	-0.05	-0.01	-0.07	-0.02

STRO Frequently Asked Questions

What is Sutro Biopharma, Inc. stock symbol ?

Sutro Biopharma, Inc. is a US stock , located in South san francisco of Ca and trading under the symbol STRO

Is Sutro Biopharma, Inc. buy or a sell ?

3 stock analysts have 3 predictions with a medium analyst target price of $19.67. The lowest prediction is $16 and the highest is $25

What is STRO stock prediction ?

What is Sutro Biopharma, Inc. stock quote today ?

Sutro Biopharma, Inc. stock price is $5.305 today.

Is Sutro Biopharma, Inc. stock public?

Yes, Sutro Biopharma, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 483.02K
Market Capitalization 322.02M
Employee 292
CEO Mr. William J. Newell J.D.
Headquarters South San Francisco,CA,US
IPO Date 2018-09-27
Website https://www.sutrobio.com

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.